BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GZR101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GZR101\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07918898-443@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:GZR101: Phase 1 readout est. (NCT07918898)
DESCRIPTION:GZR101\, phase 1.\nStudy: Comparison of Pharmacokinetic/Pharmac
 odynamic Characteristics and Safety of GZR101-80 Injection With Separately
  Injected\, Simultaneous Doses of GZR33 Injection and Insulin Aspart\nEsti
 mated primary completion: 2 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gzr101#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07918898
URL:https://assetmemo.bio/drug/gzr101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387003-443@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:GZR101: Phase 2 readout est. (NCT07387003)
DESCRIPTION:GZR101\, phase 2\, Type 2 Diabetes.\nStudy: Evaluate the Effica
 cy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes\nEst
 imated primary completion: 11 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gzr101#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07387003
URL:https://assetmemo.bio/drug/gzr101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
